U.S. Markets open in 2 hrs 25 mins

Hemispherx Biopharma Reminds Investors of Today’s Deadline to be a Stockholder of Record

To be a stockholder of record, investors are advised to own Hemispherx stock by 4:00 PM ET, Tuesday, February 12, 2019 to account for T+2 settlement timing

Record date established as Thursday, February 14, 2019

OCALA, Fla., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today issued a reminder to stockholders that the record date of its proposed rights offering is Thursday, February 14, 2019. To be a stockholder of record on the record date, ownership of Hemispherx stock must occur by market close on Tuesday, February 12, 2019 to account for settlement.

Under the proposed rights offering, Hemispherx will distribute to its holders of common stock and to holders of certain options and warrants as of February 14, 2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date. Each right will entitle the holder to purchase one unit, at a subscription price of $1,000 per unit, consisting of one share of Series B Convertible Preferred Stock with a face value of $1,000 (and immediately convertible into common stock at an assumed conversion price of $0.25) and 4,000 warrants with an assumed exercise price of $0.25.  The warrants will be exercisable for five (5) years after the date of issuance.

Subscription rights are non-transferable and may only be exercised during the anticipated subscription period of Friday, February 15, 2019 through 5:00 PM ET on Friday March 1, 2019, unless extended by Hemispherx.

The expected calendar for the rights offering, unless extended or modified in Hemispherx’ sole discretion, is as follows:

  • Tuesday, February 12, 2019: Ownership Day — in order to be considered a stockholder of record on Thursday, February 14, 2019, shares should be acquired by this date.
  • Thursday, February 14, 2019: Record Date
  • Friday, February 15, 2019: Distribution Date; Subscription Period Begins
  • Friday March 1, 2019: Subscription Period Ends 5:00 PM ET.

Holders who exercise their subscription rights in full will be entitled, if available, to subscribe for additional units that are not purchased by other stockholders, on a pro rata basis and subject to ownership limitations.

Hemispherx has engaged Maxim Group LLC and Ascendiant Capital Markets LLC as dealer-managers in the rights offering. Questions about the rights offering or requests for copies of the preliminary and final prospectuses, when available, may be directed to Maxim Group LLC at 405 Lexington Avenue, New York, NY 10174, Attention Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.

The rights offering, which is expected to commence following the effectiveness of the registration statement, is being made only by means of a written prospectus. A preliminary prospectus relating to and describing the proposed terms of the rights offering is contained in amendment no. 1 to the registration statement and is available on the SEC’s website at https://www.sec.gov/Archives/edgar/data/946644/000149315219001474/forms-1a.htm.  This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology. Hemispherx's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, Hemispherx believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® already conducted include studies of the potential treatment of cancer patients with renal cell carcinoma and malignant melanoma. These and other potential uses will require additional clinical trials to generate the safety and effectiveness data necessary to support regulatory approval. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.

Cautionary Statement
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. Among other things, no assurance can be given as to whether the ongoing or planned trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities of the Cancer Centers sponsoring these trials. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Contacts:
Hemispherx Biopharma, Inc.
Phone: 800-778-4042
Email: IR@hemispherx.net

Or

LHA Investor Relations
Miriam Weber Miller
Senior Vice President
Phone: +1-212-838-3777
Email: mmiller@lhai.com